No registrations found.
ID
Source
Brief title
Health condition
Obesity, beta2-adrenergic sensitivity, lipolysis
Obesitas, beta2-adrenerge gevoeligheid, lipolyse
Sponsors and support
Intervention
Outcome measures
Primary outcome
Changes in sensitivity to β2-AR-stimulated lipolysis in adipocytes isolated from subcutaneous adipose tissue biopsies.
Secondary outcome
1. Changes in markers of adipose tissue hypoxia;
2. Changes in markers of adipose tissue and systemic oxidative stress.
Background summary
This study investigates the effects of weight loss on beta2-adrenergic stimulated lipolysis in isolated adipocytes. In addition the effects of weight loss on adipose tissue hypoxia and adipose tissue and systemic oxidative stress will be determined.
Study objective
Moderate weight loss increases sensitivity to β2-AR-stimulated lipolysis in isolated adipocytes from subcutaneous adipose tissue biopsies.
Study design
1. Premeasurements will be done before the start of the CO-EUR programme;
2. Postmeasurements will be done after 9 months of participation in the CO-EUR programme. Postmeasurements will be done in every subject, who is still participating in the Co-Eur programme after 9 months, regardless of the amount of weight lost or gained in those 9 months.
Intervention
Subjects follow the standard weight loss programme in Heerlen (NL) provided by CO-EUR without interference by the researchers.
CO-EUR is an obesity treatment centre which uses an 18-month-lasting programme with a multi-disciplinary approach, including diet, physical activity and behaviour change, to treat people with obesity.
P.O. Box 616
K.F.M. Teunissen-Beekman
Maastricht 6200 MD
The Netherlands
+31 (0)43 3881635
kfm.teunissen@maastrichtuniversity.nl
P.O. Box 616
K.F.M. Teunissen-Beekman
Maastricht 6200 MD
The Netherlands
+31 (0)43 3881635
kfm.teunissen@maastrichtuniversity.nl
Inclusion criteria
1. All subjects entering the Co-Eur programme;
2. Age > 18 years old;
3. No more than 3 kg weight change in the past 3 months.
Exclusion criteria
1. Smoking;
2. Diabetes;
3. (Medicinal) use of β-blockers or β-agonists;
4. Pregnant women;
5. Blood clotting problems or (medicinal) use of anticoagulantia.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL2874 |
| NTR-old | NTR3019 |
| Other | METC : 11-3-019 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |